Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,225 stopped studies mapped to Malignant Genitourinary System Neoplasm and descendants · 88% state a reason
Over the 2,225 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02886546 | Utility of Dynamic Variables Measured by Calibrated Pulse Contour Analysis of Oesophageal… | N/A | terminated | Sep 1, 2016 | Hallym University Kangnam Sacred Heart Hospital | Study terminated due to lack of efficacy based on interim analysis | Efficacy / futility |
| NCT05366842 | Patient-Reported Erectile Recovery and Quality of Life Outcomes With Lyopreserved… | Phase 2 | terminated | May 9, 2022 | Johns Hopkins University | The sponsor was unable to produce and provide the study material (stravix) | Other (stated, no rule matched) |
| NCT04856189 | Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or… | Phase 1 / Phase 2 | terminated | Apr 23, 2021 | Mamta Parikh | Poor accrual. | Enrollment / accrual |
| NCT06457997 | A Study of PHN-010 in Patients With Advanced Solid Tumors | Phase 1 | terminated | Jun 13, 2024 | Pheon Therapeutics | The study was terminated by Sponsor for strategic reasons. | Sponsor / business decision |
| NCT05070247 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced… | Phase 1 / Phase 2 | terminated | Oct 7, 2021 | Takeda | Clinical Futility of TAK 500 met. No further development with this compound | Efficacy / futility |
| NCT05357027 | HPV16 E6 TCR T Cells for Cervical Carcinoma | Phase 1 / Phase 2 | terminated | May 2, 2022 | TCRCure Biopharma Ltd. | Study terminated due to strategic portfolio decision to reallocate resources to higher-priority… | Sponsor / business decision |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally… | Phase 1 / Phase 2 | terminated | Feb 7, 2020 | Ocellaris Pharma, Inc. | Business Decision | Sponsor / business decision |
| NCT05082025 | Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected… | Phase 2 | terminated | Oct 18, 2021 | M.D. Anderson Cancer Center | Copanlisib development was discontinued by Bayer following withdrawal of copanlisib in relapsed… | Other (stated, no rule matched) |
| NCT05481645 | Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib… | Phase 2 | terminated | Aug 1, 2022 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns. | Safety / toxicity |
| NCT06478862 | Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations… | Phase 2 | terminated | Jun 27, 2024 | Lipomedix Pharmaceuticals Inc. | Sponsor decision | Sponsor / business decision |
| NCT01995058 | Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With… | Phase 2 | terminated | Nov 26, 2013 | Exelixis | Sponsor decided to close the study prior to completion of enrollment. This was a business decision… | Safety / toxicity |
| NCT02948426 | Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b)… | Phase 1 | terminated | Oct 28, 2016 | National Cancer Institute (NCI) | Study was closed to accrual due to lack of drug supply. | Drug supply |
| NCT01048853 | Conservative Surgery in Treating Patients With Low-Risk Stage IA2 or IB1 Cervical Cancer | N/A | terminated | Jan 14, 2010 | M.D. Anderson Cancer Center | \< 75% participation | Other (stated, no rule matched) |
| NCT03746431 | A Phase 1 Study of [225Ac]-FPI-1434 Injection | Phase 1 | terminated | Nov 19, 2018 | Fusion Pharmaceuticals Inc. | A strategic decision was made to discontinue the study and prioritize other programs within the… | Safety / toxicity |
| NCT06545617 | A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum… | Phase 1 / Phase 2 | withdrawn | Aug 9, 2024 | Bio-Thera Solutions | Reconsideration of the subsequent international development of BAT8006 | Other (stated, no rule matched) |
| NCT03189108 | Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid Tumors | — | terminated | Jun 16, 2017 | National Cancer Institute (NCI) | PI left NIH | Investigator |
| NCT06649682 | 68Ga-NYM096/177Lu-NYM096 in Metastatic ccRCC(NYCRRLT) | Phase 1 | suspended | Oct 21, 2024 | Peking Union Medical College Hospital | This trial has been suspended given the concerns of stomach adverse effect in the first dose of… | Safety / toxicity |
| NCT06881823 | Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants…(NeoPSMA) | Phase 1 / Phase 2 | withdrawn | Mar 18, 2025 | Novartis Pharmaceuticals | The radioligands to be evaluated showed acceptable safety but limited benefit in metastatic… | Safety / toxicity |
| NCT06626256 | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable… | Phase 1 | withdrawn | Oct 3, 2024 | City of Hope Medical Center | no resource | Other (stated, no rule matched) |
| NCT04000477 | Comparison of 2 Types of Cervical Specimens in Patients With a Pathological Screening…(ENDOCOL) | N/A | terminated | Jun 27, 2019 | University Hospital, Lille | default inclusion | Other (stated, no rule matched) |
| NCT04831138 | Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy… | N/A | terminated | Apr 5, 2021 | University of Texas Southwestern Medical Center | The treatment landscape changed and hence unable to recruit patients undergoing only… | Enrollment / accrual |
| NCT06603155 | Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC) or… | N/A | withdrawn | Sep 19, 2024 | Duke University | Changing priorities of portfolio | Sponsor / business decision |
| NCT06866951 | A Clinical Study Comparing Chemotherapy Combined With PD-1 Inhibitor Versus Concurrent… | Phase 2 / Phase 3 | withdrawn | Mar 10, 2025 | Women's Hospital School Of Medicine Zhejiang University | no participants enrolled | Enrollment / accrual |
| NCT05454358 | Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP | Phase 2 / Phase 3 | terminated | Jul 12, 2022 | Fudan University | No enough participants | Other (stated, no rule matched) |
| NCT06347809 | DNA Methylation in Adenocarcinoma of the Prostate: Analysis of Validated Biomarkers in… | — | terminated | Apr 4, 2024 | Mayo Clinic | Closed to consolidate enrollment under another related study | Enrollment / accrual |
| NCT02364713 | MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian,… | Phase 2 | terminated | Feb 18, 2015 | Mayo Clinic | poor accrual | Enrollment / accrual |
| NCT04176497 | PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study | Phase 2 | terminated | Nov 25, 2019 | UNC Lineberger Comprehensive Cancer Center | Funding unavailable | Funding |
| NCT06818305 | Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function…(EmFin-Nx) | Phase 2 | terminated | Feb 10, 2025 | Jinling Hospital, China | The patient enrollment rate is proceeding too slowly | Enrollment / accrual |
| NCT07084909 | Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC(HARRIER) | Phase 2 / Phase 3 | withdrawn | Jul 25, 2025 | Lantheus Medical Imaging | Operational challenges in patient enrollment | Enrollment / accrual |
| NCT03260504 | Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney… | Phase 1 | terminated | Aug 24, 2017 | University of Washington | Insufficient funding | Funding |
| NCT05064111 | Utility of Adding MR Fusion to Standard US Guided Prostate Biopsy | — | suspended | Oct 1, 2021 | University of Arizona | Per PI, the project start is on suspension. | Other (stated, no rule matched) |
| NCT04779151 | Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and…(NIRADO) | Phase 2 | terminated | Mar 3, 2021 | Gustave Roussy, Cancer Campus, Grand Paris | Abandon of the partner, GSK | Other (stated, no rule matched) |
| NCT05252416 | (VELA) Study of BLU-222 in Advanced Solid Tumors | Phase 1 | terminated | Feb 23, 2022 | Blueprint Medicines Corporation | This trial was terminated prior to the initiation of Phase 2 for reasons not due to safety concerns. | Safety / toxicity |
| NCT04412070 | Assessement of the Concordance of Genomic Alterations Between Urine and Tissue in…(ALU) | — | terminated | Jun 2, 2020 | Hopital Foch | The target enrollment was not reached at the end of recrutement period. The presence of a… | Enrollment / accrual |
| NCT04370509 | Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients… | Phase 2 | terminated | May 1, 2020 | University of California, San Francisco | Collaborating sponsor decision | Sponsor / business decision |
| NCT03274778 | Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells | N/A | withdrawn | Sep 7, 2017 | Oncology Institute of Southern Switzerland | Recruitment difficulty due to eligibility criteria. | Enrollment / accrual |
| NCT04635059 | Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer(BLAST) | Phase 2 | terminated | Nov 18, 2020 | Medical College of Wisconsin | futility and drug supplier in favor of new metastatic protocol. | Efficacy / futility |
| NCT05256381 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety… | Phase 2 | terminated | Feb 25, 2022 | SOTIO Biotech AG | Due to lack of expected efficacy shown at the time of the interim analysis | Efficacy / futility |
| NCT06052852 | Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With… | Phase 1 | terminated | Sep 25, 2023 | Bolt Biotherapeutics, Inc. | Sponsor decision | Sponsor / business decision |
| NCT05037500 | Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate… | Phase 1 | terminated | Sep 8, 2021 | Roswell Park Cancer Institute | PI closed study | Other (stated, no rule matched) |
| NCT05119335 | A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell… | Phase 1 / Phase 2 | terminated | Nov 15, 2021 | NiKang Therapeutics, Inc. | This study was terminated as a result of Sponsor portfolio reprioritization. | Sponsor / business decision |
| NCT05935748 | Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell… | Phase 2 | terminated | Jul 7, 2023 | NiKang Therapeutics, Inc. | This study was terminated as a result of Sponsor portfolio reprioritization. | Sponsor / business decision |
| NCT04504916 | A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors… | Phase 2 | terminated | Aug 7, 2020 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Business reasons | Sponsor / business decision |
| NCT05194735 | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects… | Phase 1 / Phase 2 | terminated | Jan 18, 2022 | Alaunos Therapeutics | Funding | Funding |
| NCT05617040 | Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive… | Phase 1 / Phase 2 | terminated | Nov 15, 2022 | Barinthus Biotherapeutics | The trial was discontinued following completion of the Phase 1 portion. This discontinuation was… | Safety / toxicity |
| NCT05252390 | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients… | Phase 1 | terminated | Feb 23, 2022 | Nuvation Bio Inc. | The Sponsor has achieved its objectives. | Other (stated, no rule matched) |
| NCT05798611 | Study of ART0380 in Patients With Biologically Selected Solid Tumors(ARTIST) | Phase 2 | terminated | Apr 4, 2023 | Artios Pharma Ltd | Sponsor decision, not for reasons affecting the benefit-risk balance. | Sponsor / business decision |
| NCT04003610 | Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial… | Phase 2 | terminated | Jul 1, 2019 | Incyte Corporation | The reason this study was terminated was due to a business decision. There were no safety concerns… | Safety / toxicity |
| NCT03747419 | Avelumab and Radiation in Muscle-Invasive Bladder Cancer | Phase 2 | terminated | Nov 20, 2018 | Dana-Farber Cancer Institute | In agreement with the drug sponsor and the institution, the trial has been terminated due to slow… | Enrollment / accrual |
| NCT04586244 | An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or…(Optimus) | Phase 2 | terminated | Oct 14, 2020 | Incyte Corporation | Business Decision. No safety concerns contributed to this decision. | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jan 30, 2026source: clinicaltrials